Perspective Therapeutics Director Frank Morich Buys $14K of Stock
Frank Morich, Director, bought 15,000 shares of Perspective Therapeutics, Inc. at $0.9364 a share, worth $14K in total on Nov 16, 2026. Shares held after the trade: 30,000 (+100.0%).
Perspective Therapeutics Director Robert F. Williamson III Buys $15.6K of Stock
Robert F. Williamson III, Director, bought 18,609 shares of Perspective Therapeutics, Inc. at $0.84 a share, worth $15.6K in total on Nov 12, 2026. Shares held after the trade: 28,473 (+188.7%).
Perspective Therapeutics Director Frank Morich Buys $15K of Stock
Frank Morich, Director, bought 15,000 shares of Perspective Therapeutics, Inc. at $0.9971 a share, worth $15K in total on Nov 12, 2026. Shares held after the trade: 15,000.
Perspective Therapeutics Director Lori A. Woods Buys $20K of Stock
Lori A. Woods, Director, bought 23,750 shares of Perspective Therapeutics, Inc. at $0.8438 a share, worth $20K in total on Nov 12, 2026. Shares held after the trade: 28,557 (+494.1%).
Perspective Therapeutics CMO Markus Puhlmann Buys $29.6K of Stock
Markus Puhlmann, CMO, bought 35,000 shares of Perspective Therapeutics, Inc. at $0.8447 a share, worth $29.6K in total on Nov 12, 2026. Shares held after the trade: 178,542 (+24.4%).
Perspective Therapeutics CEO Johan M. Spoor Buys $37.9K of Stock
Johan M. Spoor, CEO, bought 47,000 shares of Perspective Therapeutics, Inc. at $0.8073 a share, worth $37.9K in total on Nov 11, 2026. Shares held after the trade: 106,383 (+79.1%).
Perspective Therapeutics reported a net loss of $85.4 million for the nine months ended September 30, 2026, compared to $65.6 million in the prior year period, primarily driven by increased research and development expenses. The company significantly strengthened its balance sheet through a 2026 registered offering, ending the period with $201.7 million in cash, cash equivalents, and short-term investments.
Perspective Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting a cash position of $202 million which is expected to fund operations into 2028. The company reported a net loss of $24.7 million for the quarter and provided clinical updates on its lead radiopharmaceutical programs, including bamzireotide navoxetan and lapemelanotide zapixetar.
Term
Q3 2026
“We have presented clinical data that demonstrated the potential of delivering alpha radiation via our proprietary targeted oncology platform. With encouraging clinical findings observed to date that further support the best‑in‑class potential of bamzireotide, continued progress across two additional programs targeting melanoma and FAP-α-positive solid tumors, and investments in our manufacturing capabilities, we are well-positioned to lead the development of the field.”
Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]lapemelanotide zapixetar (VMT01) for advanced melanoma at the SITC 2026 meeting. The data showed a 75% disease control rate at the 3.0 mCi dose level with no dose-limiting toxicities or treatment-related serious adverse events reported across 20 patients. The findings support further investigation of this targeted alpha therapy for heavily pretreated patients who have failed prior immunotherapies.
Perspective Therapeutics announced incremental Phase 1/2a clinical trial data for [212Pb]VMT-α-NET in patients with advanced neuroendocrine tumors (NETs). The data, presented at the NANETS 2026 Symposium, showed a 75% progression-free survival rate at 18 months and a 47% response rate in Cohort 3, supporting plans for a Phase 3 study initiation in 2027.
Perspective Therapeutics announced updated interim Phase 1/2a results for [212Pb]VMT-α-NET in patients with SSTR2-expressing neuroendocrine tumors, showing objective response rates of 33% and 50% in Cohorts 2 and 3, respectively. The data demonstrated a 72% progression-free survival rate at 18 months with no dose-limiting toxicities, supporting the company's plan to initiate Phase 3 trials in 2027.
Perspective Therapeutics announced that the FDA has granted Fast Track Designation for PSV359, an investigational FAP-targeted alpha-particle therapy. The designation is for the treatment of adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein-positive solitary fibrous tumors (SFTs).
Perspective Therapeutics updated its corporate presentation detailing its pipeline of next-generation radiopharmaceuticals, including clinical-stage programs VMT-α-NET, VMT01, and PSV359. The presentation highlights clinical data for its lead programs in neuroendocrine tumors and melanoma, as well as its integrated isotope production and manufacturing strategy.